Phospho-YBX1 (Ser102) Antibody

What is the YBX1 protein and why is its phosphorylation at Ser102 significant?

YBX1 (Y-Box Binding Protein 1) is a multifunctional DNA- and RNA-binding protein involved in cell proliferation, differentiation, and migration . It functions as a transcription factor that regulates gene expression in various cellular processes. YBX1 is predominantly cytoplasmic but can translocate to the nucleus under certain conditions, including DNA-damaging stress, transcription inhibition, and viral infection .

Phosphorylation at serine 102 (Ser102) is particularly significant because it activates YBX1 nuclear import . This post-translational modification serves as a regulatory mechanism for YBX1's subcellular localization and activity. In tumors, nuclear localization of YBX1 correlates with high aggressiveness, multidrug resistance, and poor prognosis, making the Ser102 phosphorylation state a potential biomarker in cancer research .

Which kinases are responsible for YBX1 Ser102 phosphorylation?

Akt kinase (also known as Protein Kinase B) has been confirmed to phosphorylate YBX1 at serine 102 . This phosphorylation event occurs in response to various stimuli, including growth factor signaling. High-throughput data from mouse adipocytes showed that levels of p-S102-containing peptides of YBX1 increased six-fold upon insulin stimulation, suggesting that insulin-activated kinases, including but not limited to Akt, can phosphorylate this residue in vivo .

The phosphorylation of YBX1 at Ser102 is stimulus-dependent and can vary across different cell systems. For example, while Akt-mediated phosphorylation occurs in response to growth factors like IGF-1 in breast cancer MCF7 cells, it was not observed in 293 cells treated with IL-1β, which instead induced phosphorylation at Ser165 .

What are the technical specifications of commercially available Phospho-YBX1 (Ser102) antibodies?

Most commercial Phospho-YBX1 (Ser102) antibodies have the following specifications:

These antibodies specifically recognize YBX1 only when phosphorylated at Ser102 and show no cross-reactivity with other proteins or non-phosphorylated YBX1 .

How should Phospho-YBX1 (Ser102) antibody be validated for experimental use?

Proper validation of Phospho-YBX1 (Ser102) antibody is crucial for experimental accuracy and should include:

• Phosphorylation-state specificity control: Use a phosphatase treatment of your samples as a negative control. The signal should disappear after phosphatase treatment if the antibody is truly phospho-specific.

• Blocking peptide control: Incubate the antibody with the phosphorylated peptide used as the immunogen before adding to samples. This competition assay should eliminate signal if the antibody is specific, as demonstrated in verification studies .

• Stimulus-dependent phosphorylation: Treat cells with known activators of Akt (e.g., IGF-1, insulin) and compare with untreated controls. An increase in signal intensity should be observed in treated samples.

• Knockdown/knockout verification: Use YBX1 knockdown or knockout cells to confirm signal specificity. No signal should be detected in these negative control samples.

• Positive control: Include a cell line known to express phosphorylated YBX1 at Ser102, such as HepG2 cells treated with PMA .

What is the optimal protocol for detecting phosphorylated YBX1 (Ser102) by Western blotting?

For optimal detection of phosphorylated YBX1 (Ser102) by Western blotting:

• Sample preparation:

  • Harvest cells in ice-cold lysis buffer containing phosphatase inhibitors (e.g., sodium fluoride, sodium orthovanadate, β-glycerophosphate)

  • Process samples immediately to prevent dephosphorylation

  • Use fresh samples when possible, as freeze-thaw cycles can reduce phospho-protein detection

• SDS-PAGE:

  • Load 20-40 μg of total protein per lane

  • Use a 10-12% acrylamide gel for optimal resolution of YBX1 (~36-50 kDa)

• Transfer and blocking:

  • Transfer to PVDF membrane (preferred over nitrocellulose for phospho-proteins)

  • Block with 5% BSA in TBST (not milk, which contains phospho-proteins that may interfere)

• Antibody incubation:

  • Dilute primary antibody 1:500-1:2000 in 5% BSA/TBST

  • Incubate overnight at 4°C with gentle rocking

  • Wash 3-5 times with TBST

  • Incubate with HRP-conjugated secondary antibody (1:5000-1:10000) for 1 hour at room temperature

  • Wash 3-5 times with TBST

• Detection:

  • Use enhanced chemiluminescence (ECL) substrate

  • For more sensitive detection, consider ECL-Plus or other enhanced sensitivity substrates

• Controls to include:

  • Positive control: Lysate from HepG2 cells treated with PMA

  • Negative control: Untreated cells or samples incubated with phosphatase

  • Loading control: Total YBX1 or housekeeping protein (e.g., GAPDH, β-actin)

How can I induce YBX1 Ser102 phosphorylation for positive control experiments?

To reliably induce YBX1 Ser102 phosphorylation for positive control experiments:

• Growth factor stimulation:

  • Serum-starve cells for 16-24 hours

  • Treat with IGF-1 (50-100 ng/ml) for 30-60 minutes

  • This activates the PI3K/Akt pathway, leading to YBX1 Ser102 phosphorylation

• Direct Akt activation:

  • Treat cells with insulin (100 nM) for 15-30 minutes to activate Akt

  • High-throughput data shows this can increase p-S102 YBX1 levels six-fold in adipocytes

• Phorbol ester treatment:

  • Treat HepG2 cells with PMA (125 ng/ml) for 15 minutes

  • This has been validated to induce YBX1 Ser102 phosphorylation

• Constitutively active Akt expression:

  • Transfect cells with a constitutively active form of Akt

  • This will lead to sustained YBX1 Ser102 phosphorylation

• Phosphatase inhibition:

  • Treat cells with phosphatase inhibitors like okadaic acid or calyculin A

  • This preserves existing phosphorylation by preventing dephosphorylation

Each approach may work differently depending on your cell type, so it's advisable to test multiple methods to determine which works best in your experimental system.

How does YBX1 phosphorylation at Ser102 interact with other post-translational modifications of YBX1?

YBX1 undergoes multiple post-translational modifications that function in an interrelated manner:

• Interplay between phosphorylation sites:

  • While Ser102 phosphorylation promotes nuclear translocation, Ser209 phosphorylation has the opposite effect, inhibiting nuclear import

  • When both Ser102 and Ser209 are phosphorylated simultaneously, the inhibitory effect of Ser209 phosphorylation dominates over the activating effect of Ser102 phosphorylation

  • The double phosphomimetic mutant (S102D-S209D) demonstrates that S209 phosphorylation inhibits S102 phosphorylation-dependent YBX1 nuclear translocation

• Stimulus-specific phosphorylation patterns:

  • Different stimuli induce distinct phosphorylation patterns

  • IL-1β treatment leads to Ser165 phosphorylation without Ser102 phosphorylation in 293 cells

  • IGF-1 treatment induces Ser102 phosphorylation in breast cancer MCF7 cells

• Functional consequences of competing modifications:

  • The balance between these phosphorylation events determines YBX1's subcellular localization and function

  • This provides a sophisticated regulatory mechanism whereby different kinase pathways can fine-tune YBX1 activity

  • Understanding this balance is crucial for interpreting experimental results when studying YBX1 function

When designing experiments to study YBX1 Ser102 phosphorylation, researchers should consider the potential influence of other post-translational modifications and include appropriate controls to account for these interactions.

What is the functional significance of YBX1 Ser102 phosphorylation in cancer biology?

YBX1 Ser102 phosphorylation plays critical roles in cancer biology:

• Regulation of nuclear translocation:

  • Ser102 phosphorylation activates YBX1 nuclear import

  • Nuclear YBX1 correlates with tumor aggressiveness, multidrug resistance, and poor prognosis

• Cell proliferation and growth:

  • Overexpression of wild-type YBX1 promotes cell growth in colon cancer HT29 cells, while knockdown of YBX1 reduces growth

  • This growth-promoting effect depends on phosphorylation, as the S165A-YBX1 mutant (another phosphorylation site) does not enhance growth

  • Similar mechanisms likely apply to Ser102 phosphorylation

• Transcriptional regulation:

  • Nuclear YBX1 regulates transcription of genes involved in:

    • Cell proliferation and survival

    • DNA repair

    • Drug resistance

    • Epithelial-mesenchymal transition

• Signaling pathway involvement:

  • Ser102 phosphorylation connects YBX1 to the PI3K/Akt pathway, a major oncogenic signaling cascade

  • This provides a mechanism by which growth factor signaling can modulate gene expression through YBX1

• Therapeutic implications:

  • Targeting YBX1 phosphorylation or the kinases responsible (such as Akt) represents a potential therapeutic strategy

  • Monitoring YBX1 Ser102 phosphorylation status could serve as a biomarker for Akt pathway activation and potentially predict response to PI3K/Akt inhibitors

How does YBX1 Ser102 phosphorylation impact its role in NF-κB signaling?

Research shows complex relationships between YBX1 phosphorylation and NF-κB signaling:

• YBX1 as an NF-κB activator:

  • YBX1 is a critical activator in IL-1β-induced NF-κB activation

  • Knockdown of YBX1 expression greatly reduces NF-κB activity in response to IL-1β

  • Overexpression of wild-type YBX1 activates NF-κB

• Phosphorylation-dependent effects:

  • While Ser165 phosphorylation (not Ser102) is specifically induced by IL-1β in 293 cells

  • The S165A-YBX1 mutant shows much reduced NF-κB activation compared to wild-type YBX1

  • This suggests phosphorylation-dependent regulation of YBX1's effect on NF-κB signaling

  • Similar mechanisms may apply to Ser102 phosphorylation in different cellular contexts

• Gene expression regulation:

  • YBX1 phosphorylation affects the expression of NF-κB-inducible genes:

    • PFKFB2 (involved in glycolysis)

    • OSM (an IL-6 family cytokine)

    • TRIM4 (involved in host defense)

  • Mutation of phosphorylation sites reduces expression of these genes

• Interplay with p65:

  • YBX1 cooperates with p65 (a component of NF-κB) to promote cell growth

  • Knockdown of p65 significantly reduces cell growth, which cannot be rescued by YBX1 overexpression

  • This suggests YBX1 promotes cell growth via interaction with p65

Researchers studying YBX1 Ser102 phosphorylation should consider its potential impact on NF-κB signaling, particularly in inflammatory contexts or cancer models where NF-κB plays a crucial role.

What are common pitfalls in detecting phosphorylated YBX1 (Ser102) and how can they be avoided?

Several challenges can arise when detecting phosphorylated YBX1 (Ser102):

• Rapid dephosphorylation during sample preparation:

  • Problem: Phosphorylated proteins can be rapidly dephosphorylated by endogenous phosphatases after cell lysis.

  • Solution:

    • Use ice-cold lysis buffer with potent phosphatase inhibitor cocktails

    • Process samples immediately without delay

    • Avoid multiple freeze-thaw cycles of protein samples

• Cross-reactivity with other phosphorylated proteins:

  • Problem: Some phospho-antibodies may recognize similar phosphorylated motifs in other proteins.

  • Solution:

    • Always validate with appropriate controls (YBX1 knockdown, blocking peptide)

    • Compare band pattern with total YBX1 antibody

    • Consider using multiple antibodies from different vendors/clones

• Antibody batch variability:

  • Problem: Different lots of the same antibody may show variable specificity and sensitivity.

  • Solution:

    • Test each new lot against a reference sample

    • Include positive and negative controls in each experiment

    • Consider purchasing larger quantities of a validated lot

• Low signal-to-noise ratio:

  • Problem: Phospho-specific antibodies often give weaker signals than total protein antibodies.

  • Solution:

    • Use enhanced sensitivity detection methods

    • Optimize antibody concentration and incubation conditions

    • Consider signal amplification techniques

    • Ensure sufficient protein loading (40-60 μg may be needed)

• Stimulus conditions not optimized:

  • Problem: Failure to detect phosphorylation despite treatment.

  • Solution:

    • Verify that the treatment conditions activate Akt (use p-Akt as a control)

    • Perform a time course to identify optimal stimulation time

    • Ensure cells are properly serum-starved before stimulation

How can I distinguish between specific YBX1 Ser102 phosphorylation signal and artifacts?

To confidently distinguish between true phospho-YBX1 (Ser102) signals and artifacts:

• Molecular weight verification:

  • YBX1 should appear at approximately 36-50 kDa (calculated MW is ~36 kDa but often runs higher)

  • Compare with total YBX1 antibody to ensure the same band is being detected

• Stimulus-responsive changes:

  • True phosphorylation signals should increase upon appropriate stimulation

  • Include both positive (stimulated) and negative (unstimulated) controls

• Blocking peptide control:

  • Pre-incubate the antibody with the phosphorylated peptide immunogen

  • The specific band should disappear or be significantly reduced

  • A dual band comparison with/without blocking peptide is shown in vendor validation images

• Phosphatase treatment control:

  • Treat half of your lysate with lambda phosphatase

  • The phospho-specific signal should disappear while total YBX1 remains unchanged

• Genetic validation:

  • Use YBX1 knockdown/knockout cells

  • Use YBX1 S102A mutant-expressing cells (this serine-to-alanine mutation prevents phosphorylation)

  • Both approaches should eliminate the specific signal

• Multiple detection methods:

  • Combine Western blotting with other methods like immunoprecipitation followed by mass spectrometry

  • This provides orthogonal validation of the phosphorylation site

How do I reconcile conflicting data regarding YBX1 phosphorylation at different sites?

Conflicting data regarding YBX1 phosphorylation is common due to its complex regulation. Here's how to approach such discrepancies:

• Consider cell type specificity:

  • Different cell types may exhibit different phosphorylation patterns

  • For example, IL-1β induces S165 but not S102 phosphorylation in 293 cells, while IGF-1 induces S102 phosphorylation in MCF7 cells

• Examine stimulus specificity:

  • Different stimuli activate distinct signaling pathways and kinases

  • Document precise treatment conditions when comparing results

• Evaluate temporal dynamics:

  • Phosphorylation is dynamic and time-dependent

  • Conduct time-course experiments to capture transient modifications

  • Early phosphorylation events may trigger subsequent modifications at different sites

• Assess interplay between modifications:

  • Phosphorylation at one site may enhance or inhibit modification at another

  • S209 phosphorylation can override the effects of S102 phosphorylation

  • Consider examining multiple phosphorylation sites simultaneously

• Control for technical variables:

  • Antibody specificity issues

  • Sample preparation differences

  • Detection method sensitivity variations

• Integrate functional readouts:

  • Connect phosphorylation data with functional outcomes (e.g., nuclear localization, transcriptional activity)

  • This helps establish which phosphorylation events are functionally dominant

  • For example, despite S102 phosphorylation promoting nuclear import, S209 phosphorylation prevents nuclear localization even when S102 is phosphorylated

When designing experiments to resolve conflicting data, consider using phosphomimetic and phospho-dead mutants (S→D/E or S→A) at multiple sites to dissect the individual and combined effects of different phosphorylation events.

How might single-cell analysis techniques advance our understanding of YBX1 Ser102 phosphorylation?

Single-cell analysis techniques offer promising avenues for understanding the heterogeneity and dynamics of YBX1 Ser102 phosphorylation:

• Capturing cellular heterogeneity:

  • Traditional biochemical methods average signals across cell populations

  • Single-cell approaches can reveal subpopulations with distinct YBX1 phosphorylation states

  • This is particularly relevant in tumors where cellular heterogeneity is pronounced

• Spatial phosphorylation dynamics:

  • Imaging mass cytometry or multiplexed immunofluorescence can map the spatial distribution of phospho-YBX1

  • This could reveal microenvironmental factors that influence YBX1 phosphorylation within tissues

• Temporal dynamics at single-cell resolution:

  • Live-cell imaging with phospho-specific biosensors could track YBX1 phosphorylation in real-time

  • This would allow visualization of phosphorylation/dephosphorylation cycles and nuclear translocation

• Correlation with cellular phenotypes:

  • Single-cell RNA-seq paired with phospho-protein detection can correlate YBX1 phosphorylation with transcriptional programs

  • This could identify gene signatures specifically associated with YBX1 Ser102 phosphorylation

• Integration with signaling networks:

  • Single-cell multi-omics approaches can map relationships between YBX1 phosphorylation and broader signaling networks

  • This would help position YBX1 Ser102 phosphorylation within the context of cellular signaling hierarchies

These advanced techniques could resolve contradictions in the literature by accounting for cellular heterogeneity and dynamic regulation that are masked in population-level studies.

What therapeutic strategies might target YBX1 Ser102 phosphorylation in disease contexts?

Based on the functional significance of YBX1 Ser102 phosphorylation, several therapeutic approaches could be considered:

• Direct inhibition of YBX1 phosphorylation:

  • Development of small molecules that specifically bind to YBX1 near the Ser102 site

  • These could prevent kinase access or induce conformational changes that make Ser102 inaccessible

• Targeting upstream kinases:

  • Akt inhibitors already in clinical development could reduce YBX1 Ser102 phosphorylation

  • This approach may have broader effects due to Akt's multiple substrates

  • Combining Akt inhibitors with readouts of YBX1 phosphorylation could help identify patients likely to respond

• Disrupting phosphorylation-dependent interactions:

  • Identification of proteins that specifically interact with phosphorylated YBX1

  • Development of protein-protein interaction inhibitors targeting these complexes

• Nuclear translocation inhibitors:

  • Since Ser102 phosphorylation promotes nuclear translocation, compounds that interfere with this process could be therapeutic

  • This might involve targeting nuclear import machinery that specifically recognizes phosphorylated YBX1

• Exploiting synthetic lethality:

  • Identifying cellular contexts where YBX1 Ser102 phosphorylation creates specific vulnerabilities

  • Developing combination therapies that target both YBX1 phosphorylation and these synthetic lethal partners

• Biomarker development:

  • Using YBX1 Ser102 phosphorylation status as a biomarker for:

    • Akt pathway activation

    • Tumor aggressiveness

    • Potential response to targeted therapies

    • Patient stratification in clinical trials

These approaches could be particularly relevant in cancers where YBX1 nuclear localization correlates with aggressive disease and poor prognosis.

What are the key considerations when incorporating phospho-YBX1 (Ser102) analysis into a research project?

When incorporating phospho-YBX1 (Ser102) analysis into a research project, consider these key factors:

• Experimental design fundamentals:

  • Include appropriate positive and negative controls

  • Design time-course experiments to capture dynamic phosphorylation

  • Consider multiple cell types to account for context-specific regulation

  • Always examine total YBX1 levels alongside phosphorylation status

• Technical optimization:

  • Validate antibody specificity with blocking peptides and phosphatase treatments

  • Optimize sample preparation to preserve phosphorylation status

  • Consider using multiple detection methods (Western blot, immunofluorescence, mass spectrometry)

• Contextual analysis:

  • Examine Akt activation status (phospho-Akt) in parallel

  • Consider analyzing multiple YBX1 phosphorylation sites (especially Ser209)

  • Connect phosphorylation data with functional readouts (nuclear localization, target gene expression)

• Interpretation caveats:

  • Recognize that correlation doesn't imply causation

  • Consider alternative kinases that might phosphorylate Ser102

  • Account for cross-talk with other post-translational modifications

  • Be aware that antibody-based detection has inherent limitations

• Translational relevance:

  • For disease-focused studies, connect YBX1 phosphorylation with clinical parameters

  • Consider how findings might inform biomarker development or therapeutic targeting